✦ LIBER ✦
546 A phase I dose-escalation trial of ZD6126 administered as 5 daily dose every 3 weeks to patients with cancer refractory to other treatments
✍ Scribed by G.T. Budd; J. Evelhoch; P. Langmuir; J. Veiero; K. Shepherdson; P. LoRusso
- Book ID
- 118620719
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 173 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.